Shares of ConjuChem Inc. plunged more than 50 percent after the company said it was temporarily stopping development of its DAC:GLP-1 compound in favor of a preclinical candidate that promises longer-term dosing to stabilize glucose levels in Type II diabetics. (BioWorld Today)